Detailed Mechanism Funding and Narrative

Years of mechanism: 2013 2014 2015 2016 2017

Details for Mechanism ID: 14766
Country/Region: Haiti
Year: 2016
Main Partner: Johns Hopkins University
Main Partner Program: JHPIEGO
Organizational Type: University
Funding Agency: USAID
Total Funding: $3,445,167 Additional Pipeline Funding: $855,694

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $29,804
Care: Orphans and Vulnerable Children (HKID) $1,084,281
Care: TB/HIV (HVTB) $197,548
Care: Pediatric Care and Support (PDCS) $152,438
Strategic Information (HVSI) $58,981
Health Systems Strengthening (OHSS) $0
Prevention: HIV Testing and Counseling (HVCT) $351,177
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $0
Treatment: Adult Treatment (HTXS) $1,452,212
Treatment: Pediatric Treatment (PDTX) $118,726
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV_DSD By PEP service provision (related to sexual violence services provided) 2017 97
GEND_GBV_DSD By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2017 10
GEND_GBV_DSD By type of service: Sexual Violence (Post-Rape Care) 2017 97
GEND_GBV_DSD Number of people receiving post-GBV care 2017 107
HTC_TST_DSD Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 48,731
HTC_TST_DSD Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 35,294
HTC_TST_DSD Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 3,915
HTC_TST_DSD Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 3,915
HTC_TST_DSD Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 91,855
HTC_TST_DSD Service Delivery Point (Facility): Inpatient 2017 582
HTC_TST_DSD Service Delivery Point (Facility): Pediatric 2017 7,833
HTC_TST_DSD Service Delivery Point (Facility): PMTCT 2017 26,776
HTC_TST_DSD Service Delivery Point (Facility): TB Clinics 2017 914
HTC_TST_DSD Service Delivery Point (Facility): VCT 2017 55,750
HTC_TST_DSD Sum of Aggregated Age/Sex 15+ 2017 84,025
HTC_TST_DSD Sum of Aggregated Age/Sex <15 2017 7,830
HTC_TST_DSD Sum of Aggregated Age/Sex disaggregates 2017 91,855
HTC_TST_DSD Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 1,456
HTC_TST_DSD Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 1,052
HTC_TST_DSD Test Result by Aggregated Age and Sex: Positive <15 Female 2017 60
HTC_TST_DSD Test Result by Aggregated Age and Sex: Positive <15 Male 2017 60
OVC_SERV_DSD By Aggregated Age/Sex: <18 Female 2017 7,565
OVC_SERV_DSD By Aggregated Age/Sex: <18 Male 2017 6,987
OVC_SERV_DSD Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS 2017 14,552
PMTCT_ART_DSD Already on ART at beginning of current pregnancy 2017 184
PMTCT_ART_DSD New on ART 2017 423
PMTCT_ART_DSD Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 26,777
PMTCT_EID_DSD By infants who received a virologic test within 2 months of birth 2017 397
PMTCT_EID_DSD By infants who received their first virologic HIV test between 2 and 12 months of age 2017 206
PMTCT_EID_DSD Number of infants with a positive virological test result within 12 months of birth 2017 5
PMTCT_EID_DSD Number of infants with a positive virological test result within 2 months of birth 2017 9
PMTCT_EID_DSD Sum of Infant Age disaggregates 2017 603
PMTCT_STAT_DSD By: Known positives at entry 2017 226
PMTCT_STAT_DSD By: Number of new positives identified 2017 414
PMTCT_STAT_DSD Number of new ANC and L&D clients 2017 27,588
PMTCT_STAT_DSD Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 26,777
PMTCT_STAT_DSD Sum of Positives Status disaggregates 2017 640
TB_ART_DSD Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 60
TB_ART_DSD Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 1
TB_ART_DSD Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 47
TB_ART_DSD Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 1
TB_ART_DSD The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2017 109
TB_ART_DSD The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2017 109
TB_SCREENDX_DSD Screen Result: Screened Positive for TB 2017 150
TB_SCREENDX_DSD Screened for TB by Age/Sex: 15+ Female 2017 4,019
TB_SCREENDX_DSD Screened for TB by Age/Sex: 15+ Male 2017 2,680
TB_SCREENDX_DSD Screened for TB by Age/Sex:<15 Female 2017 172
TB_SCREENDX_DSD Screened for TB by Age/Sex:<15 Male 2017 116
TB_SCREENDX_DSD The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 6,987
TB_SCREENDX_DSD [Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB 2017 150
TB_SCREENDX_DSD [Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert) 2017 45
TB_SCREENDX_DSD [Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only 2017 150
TB_SCREENDX_DSD [Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay 2017 22
TB_STAT_DSD Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 522
TB_STAT_DSD Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 22
TB_STAT_DSD Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 353
TB_STAT_DSD Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 17
TB_STAT_DSD Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2017 914
TB_STAT_DSD Total number of registered new and relapsed TB cases, during the reporting period 2017 934
TX_CURR_DSD Aggregated Age/Sex: 15+ Female 2017 4,019
TX_CURR_DSD Aggregated Age/Sex: 15+ Male 2017 2,680
TX_CURR_DSD Aggregated Age/Sex: <15 Female 2017 172
TX_CURR_DSD Aggregated Age/Sex: <15 Male 2017 116
TX_CURR_DSD Number of adults and children receiving antiretroviral therapy (ART) 2017 6,987
TX_CURR_DSD Sum of Aggregated Age/Sex 15+ 2017 6,699
TX_CURR_DSD Sum of Aggregated Age/Sex <15 2017 288
TX_CURR_DSD Sum of Aggregated Age/Sex disaggregates 2017 6,987
TX_NEW_DSD Aggregated Grouping by Age/Sex: 15+ Female 2017 1,381
TX_NEW_DSD Aggregated Grouping by Age/Sex: 15+ Male 2017 1,001
TX_NEW_DSD Aggregated Grouping by Age/Sex: <15 Female 2017 48
TX_NEW_DSD Aggregated Grouping by Age/Sex: <15 Male 2017 48
TX_NEW_DSD Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 2,478
TX_NEW_DSD Sum of Aggregated Age/Sex disaggregates 2017 2,478
TX_PVLS_DSD Denominator Aggregated Age/Sex: 15+ Female 2017 4,019
TX_PVLS_DSD Denominator Aggregated Age/Sex: 15+ Male 2017 2,680
TX_PVLS_DSD Denominator Aggregated Age/Sex: <15 Female 2017 172
TX_PVLS_DSD Denominator Aggregated Age/Sex: <15 Male 2017 116
TX_PVLS_DSD Denominator: Indication: Routine 2017 6,286
TX_PVLS_DSD Denominator: Indication: Targeted 2017 701
TX_PVLS_DSD Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 6,987
TX_PVLS_DSD Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 5,240
TX_PVLS_DSD Numerator Aggregated Age/Sex: 15+ Female 2017 3,014
TX_PVLS_DSD Numerator Aggregated Age/Sex: 15+ Male 2017 2,011
TX_PVLS_DSD Numerator Aggregated Age/Sex: <15 Female 2017 128
TX_PVLS_DSD Numerator Aggregated Age/Sex: <15 Male 2017 87
TX_PVLS_DSD Numerator: Indication: Routine 2017 4,716
TX_PVLS_DSD Numerator: Indication: Targeted 2017 524
TX_RET_DSD Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1,719
TX_RET_DSD Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,422
TX_RET_DSD Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1,002
TX_RET_DSD Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 830
TX_RET_DSD Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 87
TX_RET_DSD Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 72
TX_RET_DSD Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 58
TX_RET_DSD Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 47
TX_RET_DSD Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 2,371
TX_RET_DSD Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 2,866
Cross Cutting Budget Categories and Known Amounts Total: $344,069
Gender: Gender Based Violence (GBV) $344,069
GBV Prevention
Post GBV Care